BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

...hormone receptor-positive breast cancer; and that antitumor activity was greater when combined with AZ’s capivasertib, an Akt/mTOR...
BioCentury | Oct 23, 2020
Regulation

Gilead’s Veklury becomes first FDA approved COVID-19 therapy, with NIH adaptive trial as focal point

Data from NIH’s master protocol trial was the cornerstone for the first FDA approval of a COVID-19 therapy, granted to Gilead’s Veklury Thursday. The approval highlights the critical role of master protocols for generating substantive evidence...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...PARP inhibitor Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS). BMS also inherited CC-115, a dual mTOR...
...Breast cancer 1 early onset CCNE1 (CCNE) - Cyclin E1 mTOR (FRAP; RAFT1) - Mammalian target of rapamycin...
BioCentury | May 1, 2020
Distillery Therapeutics

Disrupting hypoxia signaling to treat a muscular dystrophy

...DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy The PI3K-mTOR pathway inhibitors could treat facioscapulohumeral muscular dystrophy (FSHD...
...function of components in hypoxia signaling pathway -- which can be disrupted using inhibitors of PI3K-mTOR...
...endomysial fibrosis and fat in the fin muscle. TARGET/MARKER/PATHWAY: Phosphoinositide 3-kinase (PI3K); mammalian target of rapamycin (mTOR; FRAP; RAFT1...
BioCentury | Apr 30, 2020
Deals

Adicet to become public company via resTORbio merger

...Adicet raised $80 million in October (see “OrbiMed leads series B” ). Targets mTORC1 - Mammalian target of rapamycin...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...and Guggenheim. The market reception suggests investors’ confidence that Revolution’s focus on the Ras and mTOR...
...Mammalian target of rapamycin SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Revolution Medicines Inc. Ras Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Src...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...The oncology company is developing a pipeline of small molecule therapies targeting the Ras and mTOR...
...Targets: SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2; mTOR (FRAP; RAFT1) - Mammalian target of rapamycin Hongjiang...
...Medicines Inc. Genmab A/S Johnson & Johnson Adaptimmune Therapeutics plc PDC*line Pharma Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)...
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...translation of proteins that support the growth and proliferation of cancer cells when activated by PI3K/mTOR...
...kinase 1 MKNK2 (MNK2) - MAP kinase interacting serine-threonine kinase 2 mTOR (FRAP; RAFT1) - Mammalian target of rapamycin...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...from BioCentury’s BCIQ database. Targets ALDOS (CYP11B2) - Aldosterone synthase KRAS - K-Ras mTORC1 - Mammalian target of rapamycin...
Items per page:
1 - 10 of 781